Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1267-1275

  Nie, Ting ^a   Detorio, Mervi ^a   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 3' AZIDO 2',3' DIDEOXYPURINE RIBOSIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; POL PROTEIN; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE;

AMPLICON; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION PROFILING; GENETIC CODE; GENETIC IDENTIFICATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE GENE; IN VITRO STUDY; INTEGRASE GENE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE GENE; RNASE H GENE; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS TYPING;

ANTI-HIV AGENTS; CLONING, MOLECULAR; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, VIRAL; ESCHERICHIA COLI; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD; VIRAL PROTEINS;

EID: 83455199994     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1892     Document Type: Article

References (25)

1. Martínez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008; 10:212-223.
2. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004; 29:152-159. (Pubitemid 38201460)
3. Katzenstein D. Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. J Infect Dis 2006; 194 Suppl 1:S45-S50. (Pubitemid 44420872)
4. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51:229-240. (Pubitemid 36231141)
5. Brennan CA, Stramer SL, Holzmayer V, et al. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion 2009; 49:125-133.
6. Osmanov S, Pattou C, Walker N, Schwardländer B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29:184-190. (Pubitemid 34164892)
7. Lu W, Cao L, Ty L, Arlie M, Andrieu JM. Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: applications for universal detection and quantitation. Nat Med 1999; 5:1081-1085. (Pubitemid 29439584)
8. Tang N, Huang S, Salituro J, et al. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007; 146:236-245. (Pubitemid 350026638)
9. Van Laethem K, Schrooten Y, Covens K, et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008; 153:176-181.
10. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5:25-35. (Pubitemid 36873892)
11. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010; 26:489-493.
12. Nkolola JP, Essex M. Progress towards an HIV-1 subtype C vaccine. Vaccine 2006; 24:391-401. (Pubitemid 41832541)
13. Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004; 18 Suppl 3:S63-S68. (Pubitemid 39037462)
14. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29:296-299. (Pubitemid 32054474)
15. Wittek M, Stürmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn 2007; 7:237-246. (Pubitemid 46798614)
16. Rhee SY, Liu TF, Kiuchi M, et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008; 5:74.
17. Roquebert B, Marcelin AG. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother 2008; 61:973-975. (Pubitemid 351524436)
18. Santos AF, Lengruber RB, Soares EA, et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008; 3:e1781.
19. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4:e335.
20. Tebit DM, Nankya I, Arts EJ, Gao Y. HIV diversity, recombination and disease progression: how does fitness 'fit' into the puzzle? AIDS Rev 2007; 9:75-87. (Pubitemid 47162247)
21. Zhang HW, Coats SJ, Bondada L, et al. Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorg Med Chem Lett 2010; 20:60-64.
22. Leoz M, Depatureaux A, Vessière A, et al. Integrase polymorphism and HIV-1 group O diversity. AIDS 2008; 22:1239-1243.
23. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84:9210-9216.
24. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 2004; 10:4055-4064. (Pubitemid 39654467)
25. Lambert-Niclot S, Flandre P, Malet I, et al. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J Antimicrob Chemother 2008; 62:905-908.